Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population

Pharmacological Reports

Volumn 59, Issue 2, 2007, Pages 199-205

  Kotrych, Katarzyna ^a   Sulikowski, Tadeusz ^a   Domański, Leszek ^a   Białecka, Monika ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

MDR1 gene; P glycoprotein; Polymorphism; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYSTEINE; DILTIAZEM; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THREONINE; VERAPAMIL;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ALLOGRAFT; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DNA EXTRACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EXON; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; POLAND; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

EID: 34250751261     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther, 2004, 75, 422-433.
2. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffler M et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther, 2001, 69, 169-174.
3. Droździk M, Białecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetic, 2003, 13, 259-263.
4. Droździk M, Kurzawski M, Droździk A, Kotrych K, Banach J, Pawlik A: Interleukin-6 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol, 2005, 32, 955-958.
5. Gustincich S, Manfiolett G, Del Sal G, Schneider C, Carninci P: A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques, 2001, 11, 289-300.
6. Hitzl M, Drescher S, van der Kuip H, Schaeffter E, Fischer J, Schwab M, Eichelbaum M et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 - natural killer cells. Pharmacogenetics, 2001, 11, 291-298.
7. Hoffmeyer S, Bulk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3474-3478.
8. Jamroziak K, Balcerczak E, Młynarski W, Mirowski M, Robak T: Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDRI gene in a sample of Polish population. Pol J Pharmacol, 2002, 54, 493-600.
9. Kotrych K, Domański L, Górnik W, Droździk M: The MDR1 gene polymorphism in allogenic kidney transplant patients with tremor. Pharmacol Rep, 2005, 57, 241-245.
10. Kuzuya T, Kobayashi T, Moriyama N, Hnagasaka T, Yokoyama I, Uchida K, Nakao A et al.: Amlodipine, but not MDR1 polymorphism, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation, 2003, 76, 865-868.
11. Lo A, Burcart GJ: P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol, 1999, 39, 995-1005.
12. Longuemaux S, Delomenie C, Gallou C, Mejean A. Vincent-Viry M, Bouvier R, Droz D et al.: Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res, 1999, 59, 2903-2908.
13. Lown KS, Mayo RR, Leichtmań AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB et al.: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther, 1997, 62, 248-260.
14. Mai I, Stromer E, Goldammer M, Johne A, Kruger H, Budde K, Roots I: MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol, 2003, 43, 1101-1107.
15. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K. Inui K: Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther, 2000, 68, 98-103.
16. Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol, 1998, 161, 5733-5744.
17. Raghu G, Park SW, Roninson IB. Mechetner EB: Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol, 1996, 24, 1258-1264.
18. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 2002, 25, 1391-1400.
19. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, 2001, 358, 383-184.
20. Schinkel A, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995, 96, 1698-1705.
21. Schwab M, Eichelbaum M, Fromm M.F: Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol, 2004, 43, 285-307.
22. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroentrology, 2003, 124, 26-33.
23. Siegsmund M, Brinkmann U, Schaeffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P et al.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol, 2002, 13, 1847-1854.
24. The EBPG Expert Group on Renal Transplantation: Nephrol Dial Tansplant, 2000, 15, 7-32.
25. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem, 2001, 47, 1048-1052.
26. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003, 43, 555-564.
27. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, Zhang J et al.: The impact of pharmacogenomic factors on acute persitent rejection in adult lung transplant patients. Transpl Immunol, 2005, 14, 37-42.